Skip to main
CAPR
CAPR logo

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc. is actively advancing its lead product, deramiocel, through Phase 3 clinical development for Duchenne muscular dystrophy, supported by a successful partnership that enhances its operational runway and positions the company for future commercialization efforts in Europe. The therapeutic has demonstrated a favorable long-term benefit-risk profile without new safety concerns, signaling strong potential for market acceptance and efficacy. Positive developments in regulatory discussions further mitigate risks, enhancing the overall outlook for Capricor’s share value as investors respond to encouraging milestones in deramiocel's pathway.

Bears say

Capricor Therapeutics Inc's recent clinical data for deramiocel indicates a modest reduction in disease progression, yet the observed mean annual decline in Performance of the Upper Limb 2.0 (PUL 2.0) scores raises concerns about the efficacy of the treatment, with differences in performance highlighting the potential for inconclusive trial results. The company faces significant challenges in securing sufficient funding to advance its drug development, which adds uncertainty to its financial stability and prospects for advancing its lead products. Additionally, the risk of failing or inconclusive clinical trials could severely hinder Capricor's ability to achieve its strategic objectives and adversely impact investor confidence in the stock.

Capricor Therapeutics (CAPR) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.